For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost - STAT

For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost - STAT

For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

By KATE SHERIDAN

ALEX HOGAN/STAT; ADOBE

The storied San Francisco conference gives small companies a pivotal and unmissable chance to wow potential investors and plan the year ahead.

READ MORE